{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:58:48Z","timestamp":1781020728699,"version":"3.54.1"},"reference-count":39,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000098","name":"Clinical Center","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000098","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["ZIA BC 011823"],"award-info":[{"award-number":["ZIA BC 011823"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"U.S. Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100031022","name":"Center for Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031022","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["celltherapyjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cytotherapy"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.jcyt.2026.102788","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T17:28:52Z","timestamp":1773854932000},"page":"102788","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia"],"prefix":"10.1016","volume":"28","author":[{"given":"Anna","family":"Cantilena","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu Lee","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3693-9533","authenticated-orcid":false,"given":"Yihua","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4288-3037","authenticated-orcid":false,"given":"Bonnie","family":"Yates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5867-3265","authenticated-orcid":false,"given":"David","family":"Stroncek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Dreyzin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jcyt.2026.102788_bib0001","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1093\/oncolo\/oyac085","article-title":"Utilization of immunotherapy in patients with cancer treated in routine care settings: a population-based study using health administrative data","volume":"27","author":"Raphael","year":"2022","journal-title":"Oncologist"},{"issue":"3","key":"10.1016\/j.jcyt.2026.102788_bib0002","doi-asserted-by":"crossref","DOI":"10.1200\/EDBK-25-472778","article-title":"Navigating B-ALL in the era of blinatumomab","volume":"45","author":"Zupanec","year":"2025","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102788_bib0003","doi-asserted-by":"crossref","first-page":"5887","DOI":"10.1182\/blood-2024-210200","article-title":"Application of inotuzumab ozogamicin in children with B-ALL","volume":"144","author":"Chi","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102788_bib0004","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41408-024-01092-w","article-title":"Efficacy of blinatumomab as maintenance therapy for B-lineage acute lymphoblastic leukemia\/lymphoma following allogeneic hematopoietic cell transplantation","volume":"14","author":"Huang","year":"2024","journal-title":"Blood Cancer J"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102788_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29715","article-title":"Blinatumomab overcomes poor prognostic impact of measurable residual disease in pediatric high-risk first relapse B-cell precursor acute lymphoblastic leukemia","volume":"69","author":"Locatelli","year":"2022","journal-title":"Pediatr Blood Cancer"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102788_bib0006","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"New England Journal of Medicine"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102788_bib0007","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2411680","article-title":"Blinatumomab in standard-risk B-cell acute lymphoblastic leukemia in children","volume":"392","author":"Gupta","year":"2025","journal-title":"New Engl J Med"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102788_bib0008","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","article-title":"Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions","volume":"17","author":"Short","year":"2024","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jcyt.2026.102788_bib0009","series-title":"FDA approves inotuzumab ozogamicin for pediatric patients with acute lymphoblastic leukemia","year":"2024"},{"issue":"1","key":"10.1016\/j.jcyt.2026.102788_bib0010","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/s41375-022-01740-9","article-title":"Outcome of chimeric antigen receptor T-cell therapy following treatment with inotuzumab ozogamicin in children with relapsed or refractory acute lymphoblastic leukemia","volume":"37","author":"Ceolin","year":"2023","journal-title":"Leukemia"},{"issue":"9","key":"10.1016\/j.jcyt.2026.102788_bib0011","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1200\/JCO.21.01405","article-title":"Blinatumomab nonresponse and high-disease burden are associated with inferior outcomes after CD19-CAR for B-ALL","volume":"40","author":"Myers","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jcyt.2026.102788_bib0012","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1182\/blood-2021-146556","article-title":"Potential impact of treatment with inotuzumab ozogamicin on chimeric antigen receptor T-cell therapy in children with relapsed or refractory acute lymphoblastic leukemia","volume":"138","author":"Valeria","year":"2021","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102788_bib0013","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1182\/blood-2023-183103","article-title":"Impact of treatment with inotuzumab ozogamicin before or after chimeric antigen receptor T-cell therapy in children with relapsed\/refractory acute lymphoblastic leukemia","volume":"142","author":"Rheingold","year":"2023","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102788_bib0014","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10112915","article-title":"Blinatumomab prior to CAR-T cell therapy-a treatment option worth consideration for high disease burden","volume":"10","author":"Marschollek","year":"2022","journal-title":"Biomedicines"},{"issue":"15_suppl","key":"10.1016\/j.jcyt.2026.102788_bib0015","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.10518","article-title":"Tisagenlecleucel (Tisa) for relapsed\/refractory (r\/r) acute lymphoblastic leukemia (ALL): B2001X study focusing on prior exposure to blinatumomab (BLINA) and inotuzumab (INO)","volume":"38","author":"Krueger","year":"2020","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1016\/j.jcyt.2026.102788_bib0016","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.jcyt.2026.102788_bib0017","doi-asserted-by":"crossref","first-page":"1743","DOI":"10.1182\/blood-2021-148820","article-title":"Outcomes of children and young adults with acute lymphoblastic leukaemia administered inotuzumab Pre CAR-T therapy","volume":"138","author":"Khushnuma","year":"2021","journal-title":"Blood"},{"issue":"22","key":"10.1016\/j.jcyt.2026.102788_bib0018","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1182\/bloodadvances.2019000692","article-title":"CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy","volume":"3","author":"Pillai","year":"2019","journal-title":"Blood Advances"},{"issue":"8","key":"10.1016\/j.jcyt.2026.102788_bib0019","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007118","article-title":"Impact of prior therapies and subsequent transplantation on outcomes in adult patients with relapsed or refractory B-cell acute lymphoblastic leukemia treated with brexucabtagene autoleucel in ZUMA-3","volume":"11","author":"Shah","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"23","key":"10.1016\/j.jcyt.2026.102788_bib0020","doi-asserted-by":"crossref","first-page":"6137","DOI":"10.1182\/bloodadvances.2024014237","article-title":"Impact of prior treatment on CAR T-cell outcome in adult ALL","volume":"8","author":"Marks","year":"2024","journal-title":"Blood Advances"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102788_bib0021","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1111\/bjh.19104","article-title":"Blinatumomab differentially modulates peripheral blood and bone marrow immune cell repertoire: a campus ALL study","volume":"203","author":"Ocadlikova","year":"2023","journal-title":"Br J Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102788_bib0022","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1182\/blood-2024-194670","article-title":"T-cell receptor signaling and dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia","volume":"144","author":"Ma","year":"2024","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102788_bib0023","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory T cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with B-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102788_bib0024","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood-2023-188970","article-title":"Single-cell transcriptomic profiling of T cells from blinatumomab-treated patients with B-cell precursor acute lymphoblastic leukemia (BCP-ALL) reveals circulating CD8 T cell subsets associated with treatment response","volume":"142","author":"Corrado","year":"2023","journal-title":"Blood"},{"issue":"23","key":"10.1016\/j.jcyt.2026.102788_bib0025","doi-asserted-by":"crossref","first-page":"6139","DOI":"10.1182\/bloodadvances.2024013747","article-title":"Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL","volume":"8","author":"Aldoss","year":"2024","journal-title":"Blood Advances"},{"issue":"5","key":"10.1016\/j.jcyt.2026.102788_bib0026","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nature Med"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102788_bib0027","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2023-182222","article-title":"Apheresis for production of chimeric antigen receptor (CAR) T cells in patients with multiple myeloma - clinical factors, cell composition and t cell senescence","volume":"142","author":"Vucinic","year":"2023","journal-title":"Blood."},{"issue":"2, Supplement","key":"10.1016\/j.jcyt.2026.102788_bib0028","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.jtct.2023.12.258","article-title":"Apheresis product characteristics predict response to CD22 CAR T-cell therapy in pediatric and young adult patients with B-ALL","volume":"30","author":"Dreyzin","year":"2024","journal-title":"Transplantation and Cellular Therapy"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102788_bib0029","doi-asserted-by":"crossref","first-page":"7267","DOI":"10.1182\/blood-2024-194108","article-title":"Predictors of apheresis product quality and impact on clinical outcomes in chimeric antigen receptor T-cell therapy for R\/R DLBCL and B-ALL","volume":"144","author":"Lee","year":"2024","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jcyt.2026.102788_bib0030","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"issue":"15","key":"10.1016\/j.jcyt.2026.102788_bib0031","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1182\/bloodadvances.2025015894","article-title":"T-cell dysfunction during blinatumomab therapy in pediatric acute lymphoblastic leukemia","volume":"9","author":"Ma","year":"2025","journal-title":"Blood Adv"},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102788_bib0032","doi-asserted-by":"crossref","first-page":"3334","DOI":"10.1182\/blood-2018-99-111576","article-title":"Improved expansion and function of CAR T cell products from cultures initiated at defined CD4:CD8 ratios","volume":"132","author":"Lee","year":"2018","journal-title":"Blood"},{"issue":"10254","key":"10.1016\/j.jcyt.2026.102788_bib0033","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jcyt.2026.102788_bib0034","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007803","article-title":"CD8(+) chimeric antigen receptor T cells manufactured in absence of CD4(+) cells exhibit hypofunctional phenotype","volume":"11","author":"Lee","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.jcyt.2026.102788_bib0035","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/leu.2015.247","article-title":"Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo","volume":"30","author":"Sommermeyer","year":"2016","journal-title":"Leukemia"},{"issue":"669","key":"10.1016\/j.jcyt.2026.102788_bib0036","doi-asserted-by":"crossref","first-page":"eabq1693","DOI":"10.1126\/scitranslmed.abq1693","article-title":"Dynamics of T cell repertoire renewal following autologous hematopoietic stem cell transplantation in multiple sclerosis","volume":"14","author":"Ruder","year":"2022","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jcyt.2026.102788_bib0037","doi-asserted-by":"crossref","first-page":"507","DOI":"10.3389\/fimmu.2016.00507","article-title":"Immune reconstitution after allogeneic hematopoietic stem cell transplantation","volume":"7","author":"Ogonek","year":"2016","journal-title":"Front Immunol"},{"issue":"10","key":"10.1016\/j.jcyt.2026.102788_bib0038","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.3109\/10428194.2010.503820","article-title":"Prognostic significance of CD8 and CD4 T cells in chronic lymphocytic leukemia","volume":"51","author":"Ana","year":"2010","journal-title":"Leukemia \\& Lymphoma."},{"issue":"Supplement 1","key":"10.1016\/j.jcyt.2026.102788_bib0039","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood-2018-99-119409","article-title":"Altered T cell subsets and function in patients with acute lymphoblastic leukemia","volume":"132","author":"Leonard","year":"2018","journal-title":"Blood"}],"container-title":["Cytotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007498?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1465324926007498?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T15:19:18Z","timestamp":1781018358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1465324926007498"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":39,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S1465324926007498"],"URL":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102788","relation":{},"ISSN":["1465-3249"],"issn-type":[{"value":"1465-3249","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of blinatumomab and inotuzumab exposure on apheresis composition for CAR T in patients with B-cell acute lymphoblastic leukemia","name":"articletitle","label":"Article Title"},{"value":"Cytotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcyt.2026.102788","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Society for Cellular Therapy.","name":"copyright","label":"Copyright"}],"article-number":"102788"}}